https://t.co/xeDZ27Rexi what's actually in it:
→ 189 research vendors
→ 1,012 COAs on file, 807 published, 238 matched against the issuing lab's own records. 13 labs, 57 compounds.
→ 2,700+ providers — telehealth, clinics, 503A/503B pharmacies, filterable by country / state, type, and compound carried.
→ 118 compounds, each graded by how much published research exists, with current regulatory status.
→ 1,279 vendor prices across 44 compounds, re-captured weekly. Median $/mg with the full range. (Being upgraded)
→ FDA vote tracker.
→ And more
No account needed. No payment.
0 paid placements no vendor, provider or affiliate has ever paid us a dollar.
More coming.
🚨Who buys from this pharmacy?
Greenwich Rx also got a California cease-and-desist in May: 253k prescriptions shipped there unlicensed.
Telehealths linked to it (GLP-1s): Amble, Trimi, Elara, Gimme Care, Coby Health.
None is confirmed as selling the recalled lots.
🚨Breaking: A Texas compounding pharmacy is recalling 261 lots of injectables after an FDA inspection.
They include BPC-157, TB-500, MOTS-c, semaglutide and tirzepatide. No contamination or side effects found, per the company.
Did you get shots from Greenwich Rx?
📉 Pennsylvania's Medicaid stopped covering GLP-1s for weight loss on Jan 1.
Within three months, those prescriptions fell 95.5%.
Across the 4 states that ended coverage that day (CA, NH, PA, SC):
• Prescriptions: 661,353 → 134,647 a quarter
• Almost no one switched to older weight-loss drugs
Counts prescriptions, not people. Latest quarter is provisional (Cureus).
What happens when treatment just stops?
🌍 What if everyone with obesity took a GLP-1?
Researchers modelled the world in 2050 (Nature Communications, Nov 19):
• People eat fewer calories, so less farmland is needed
• 32M hectares go back to nature, an area bigger than Italy
• Up to 6.6M fewer deaths that year
Pair it with healthier diets: 46M hectares and 7.7M fewer deaths.
It's a computer simulation, not real-world data.
The FDA still has no permanent chief, as it decides the final rule on six peptides.
The White House pulled Heidi Overton's nomination Nov 17, the night before a Senate committee vote. The agency has had no confirmed commissioner since Marty Makary left in May.
Acting head: Kyle Diamantas, a lawyer who runs FDA's food division.
Does this slow the peptide decision?
📊 Australia's drug regulator tested vials sold as "KLOW." It found no TB-500 in them.
TGA lab results on Synedica-brand products:
• KLOW 80 mg: no TB-500 detected
• BARBIE KLOW 100 mg: no TB-500 detected
• BPC-157 & TB-500 10 mg: no TB-500 detected
• Retatrutide 10 mg: less than labelled, varied between samples
In the US, Enhanced told investors Nov 12 it will soon sell KLOW, GLOW and Wolverine bundles.
Do you know what's in your blend?
🇦🇺 Australia's health minister just asked parliament to investigate peptides.
Mark Butler wrote to parliament's health committee on Friday requesting an inquiry into online peptide prescribing.
What's behind it, per ABC News:
• NSW hospital visits linked to unapproved peptides: 5 in July 2025 → 217 in September 2026 (monthly)
• Poisons centre: 345 cases in the first half of 2026, more than triple all of 2025
The inquiry covers telehealth and one-stop dispensaries, plus social media promotion.
Hearings start this month. Final report due mid-2027.
The US is loosening. Australia is tightening.
🚨 A vial sold online as "retatrutide" tested as semaglutide, the drug in Ozempic, per a federal plea deal.
The Florida seller, AKT Labs owner Adam Taylor, signed the deal Nov 18. His site said "for research purposes only."
How sure are you what's in your vial?
Source: ABC News, 22 Nov 2026 — https://t.co/XabhpLpg3d
Butler: "I know peptides are often marketed on social media as 'wonder-drugs' but the reality is that they can pose serious health risks to Australian consumers."
🚨 A vial sold online as "retatrutide" tested as semaglutide, the drug in Ozempic, per a federal plea deal.
The Florida seller, AKT Labs owner Adam Taylor, signed the deal Nov 18. His site said "for research purposes only."
How sure are you what's in your vial?
🇬🇧 The UK's pharmacy regulator just opened an investigation into two online pharmacies.
A healthy-weight Mirror reporter used AI to make her photos look overweight. Two of three sent her Wegovy pills, per the paper.
Should a photo be enough to get a weight-loss drug? 👀
🚨Update: The FDA inspection behind this week's Texas peptide-shot recall listed 14 problems.
Inspectors found microbes in a sterile hood on a day it made semaglutide, tirzepatide and BPC-157. These are observations, not final FDA findings.
🚨Breaking: The national group for state medical boards says HHS's peptide policy doesn't change state law, per write-ups of a Nov 10 FAQ.
Following HHS's rules for BPC-157, TB-500 and 4 others doesn't by itself meet state requirements.
Kentucky already said don't compound them. Who's next?
💸 Zepbound users had 34% fewer hospital and ER visits after 12–18 months than similar untreated adults.
Lilly's data on 171,000 people taking its weight-loss drug, per Reuters. Their healthcare costs held flat, not counting the drug.
🚨Update: The FDA inspection behind this week's Texas peptide-shot recall listed 14 problems.
Inspectors found microbes in a sterile hood on a day it made semaglutide, tirzepatide and BPC-157. These are observations, not final FDA findings.
🚨Breaking: A Texas compounding pharmacy is recalling 261 lots of injectables after an FDA inspection.
They include BPC-157, TB-500, MOTS-c, semaglutide and tirzepatide. No contamination or side effects found, per the company.
Did you get shots from Greenwich Rx?
🚨Breaking: A Texas compounding pharmacy is recalling 261 lots of injectables after an FDA inspection.
They include BPC-157, TB-500, MOTS-c, semaglutide and tirzepatide. No contamination or side effects found, per the company.
Did you get shots from Greenwich Rx?
Kentucky won't be the only state to block these six peptides.
HHS said it won't enforce federal law. It didn't touch state law, and pharmacy boards answer to state law.
Where states stand today:
🔴 Kentucky: blocked
🔴 Ohio: BPC-157 already not allowed
🟡 Arizona, Illinois, Massachusetts: undecided
🟢 Utah: following HHS
Most states haven't picked a side yet.
🚨 Kentucky's pharmacy board has now posted its alert: no compounding of BPC-157, TB-500, Epitalon, Semax, KPV or MOTS-c in or into the state.
Pharmacies must pull existing stock, and the board won't consider waivers.
Will other state boards follow?
🇰🇷 Koreans are heading to Japan for cheaper Mounjaro, per Newsis.
Since Nov 12, Korea lets people bring back up to 3 months of meds prescribed abroad.
4 weeks of the starter dose: ₩250K–300K+ in Korea vs ~₩60K–100K in Japan.
Would you fly abroad for a cheaper GLP-1?
📊 About 3 in 4 people who got GLP-1s via telehealth or med spas used compounded versions, a new study found.
Via a doctor or pharmacy: about 1 in 8. Online buyers also skipped doses over cost more often.
Where did you get yours?
🚨Breaking: A Texas compounding pharmacy is recalling 261 lots of injectables after an FDA inspection.
They include BPC-157, TB-500, MOTS-c, semaglutide and tirzepatide. No contamination or side effects found, per the company.
Did you get shots from Greenwich Rx?
🚨A federal judge let a class action over compounded "oral tirzepatide" pills move ahead.
The suit calls the pills "modern-day snake oil" and targets a pharmacy and telehealth firms. The claims are unproven.